EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Disease modeling and pharmacological rescue of autosomal dominant retinitis pigmentosa associated with RHO copy number variation

Sangeetha Kandoi, Cassandra Martinez, Kevin Xu Chen, Miika Mehine, L Vinod K Reddy, Brian C Mansfield, Jacque L Duncan, Deepak A Lamba

eLife · 25.04.2024 · 12

DOI: 10.7554/elife.90575.3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift eLife, online erschienen am 25.04.2024. Verfasst von Sangeetha Kandoi und 7 weiteren Autor:innen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: California Institute for Regenerative Medicine, National Eye Institute, Foundation Fighting Blindness.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Retinitis pigmentosa (RP), a heterogenous group of inherited retinal disorder, causes slow progressive vision loss with no effective treatments available. Mutations in the rhodopsin gene ( RHO ) account for ~25% cases of autosomal dominant RP (adRP). In this study, we describe the disease characteristics of the first-ever reported mono-allelic copy number variation (CNV) in RHO as a novel cause of adRP. We (a) show advanced retinal degeneration in a male patient (68 years of age) harboring four transcriptionally active intact copies of rhodopsin, (b) recapitulated the clinical phenotypes using retinal organoids, and (c) assessed the utilization of a small molecule, Photoregulin3 (PR3), as a clinically viable strategy to target and modify disease progression in RP patients associated with RHO -CNV. Patient retinal organoids showed photoreceptors dysgenesis, with rod photoreceptors displaying stunted outer segments with occasional elongated cilia-like projections (microscopy); increased RHO mRNA expression (quantitative real-time PCR [qRT-PCR] and bulk RNA sequencing); and elevated levels and mislocalization of rhodopsin protein (RHO) within the cell body of rod photoreceptors (western blotting and immunohistochemistry) over the extended (300 days) culture time period when compared against control organoids. Lastly, we utilized PR3 to target NR2E3 , an upstream regulator of RHO , to alter RHO expression and observed a partial rescue of RHO protein localization from the cell body to the inner/outer segments of rod photoreceptors in patient organoids. These results provide a proof-of-principle for personalized medicine and suggest that RHO expression requires precise control. Taken together, this study supports the clinical data indicating that RHO-CNV associated adRPdevelops as a result of protein overexpression, thereby overloading the photoreceptor post-translational modification machinery.

Förderung

  • California Institute for Regenerative Medicine
  • National Eye Institute
  • Foundation Fighting Blindness
  • All May See Foundation
  • BrightFocus Foundation
  • Research to Prevent Blindness

Zitieren

APA

Kandoi, S., Martinez, C., Chen, K. X., Mehine, M., Reddy, L. V. K., Mansfield, B. C., Duncan, J. L., & Lamba, D. A. (2024). Disease modeling and pharmacological rescue of autosomal dominant retinitis pigmentosa associated with RHO copy number variation. eLife, 12. https://doi.org/10.7554/elife.90575.3

Vancouver

Kandoi S, Martinez C, Chen KX, Mehine M, Reddy LVK, Mansfield BC, et al. Disease modeling and pharmacological rescue of autosomal dominant retinitis pigmentosa associated with RHO copy number variation. eLife. 2024;12. doi:10.7554/elife.90575.3

BibTeX
@article{Kandoi2024,
  author = {Kandoi, Sangeetha and Martinez, Cassandra and Chen, Kevin Xu and Mehine, Miika and Reddy, L Vinod K and Mansfield, Brian C and Duncan, Jacque L and Lamba, Deepak A},
  title = {Disease modeling and pharmacological rescue of autosomal dominant retinitis pigmentosa associated with RHO copy number variation},
  journal = {eLife},
  year = {2024},
  volume = {12},
  doi = {10.7554/elife.90575.3}
}
Kostenlos starten →